Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia

NCT03291353 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped This study has closed due to slow accrual.

Conditions

Refractory Acute Myeloid Leukemia

Interventions

DRUG: pembrolizumab

Sponsor

Michael Boyiadzis

Collaborators

[object Object]